Share Price and Basic Stock Data
Last Updated: January 13, 2026, 4:27 am
| PEG Ratio | 10.20 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ganga Pharmaceuticals Ltd operates within the pharmaceutical industry, reporting a market capitalization of ₹6.90 Cr and a share price of ₹11.70. The company’s revenue from operations showed fluctuations over the years, with sales recorded at ₹2.47 Cr for the financial year ending March 2023, slightly rising to ₹2.58 Cr in March 2024. However, the trailing twelve months (TTM) revenue stood at ₹2.70 Cr, indicating a slight recovery from the previous year’s figures. Quarterly sales data for September 2023 reported ₹1.32 Cr, reflecting a modest increase from ₹1.23 Cr in March 2023. The company has experienced volatility in sales, particularly evident in the drop to ₹1.14 Cr in September 2020, suggesting challenges in maintaining consistent revenue generation. This inconsistency may be attributed to market dynamics and competitive pressures within the pharmaceutical sector.
Profitability and Efficiency Metrics
Ganga Pharmaceuticals’ profitability metrics exhibit significant challenges, as evidenced by its operating profit margin (OPM), which recorded -1.46% for the year ending March 2025. This negative margin indicates that the company has been unable to cover its operating expenses, a trend that has persisted with OPM fluctuating from 20.29% in September 2019 to a low of -5.69% in March 2023. The return on equity (ROE) stood at a mere 1.13%, underscoring inefficiencies in generating returns for shareholders. Additionally, the interest coverage ratio (ICR) was reported at 1.79x, suggesting a limited ability to cover interest expenses, although it remains above the critical threshold of 1.5x. The cash conversion cycle (CCC) at 403.19 days reflects operational inefficiencies, indicating a prolonged period to convert investments into cash flow, which is considerably high compared to typical sector benchmarks.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ganga Pharmaceuticals shows a mix of strengths and weaknesses. Total assets recorded at ₹10.16 Cr as of September 2025, with total liabilities at ₹8.97 Cr, indicating a healthy asset-to-liability ratio. The company’s borrowings stood at ₹1.56 Cr, reflecting a conservative leverage position, especially with a long-term debt-to-equity ratio of 0.03. However, the return on capital employed (ROCE) was reported at 3.18%, indicating suboptimal utilization of capital. The price-to-book value (P/BV) ratio was calculated at 0.68x, suggesting that the stock may be undervalued relative to its book value, which stood at ₹14.74 per share. The current ratio of 4.28x indicates strong liquidity, ensuring that the company can meet its short-term obligations, thereby providing a buffer against financial distress.
Shareholding Pattern and Investor Confidence
Ganga Pharmaceuticals’ shareholding pattern demonstrates a significant shift in promoter ownership, declining from 66.71% in June 2021 to 50.91% by September 2025. This reduction may raise concerns regarding insider confidence in the company’s future performance. Public shareholders accounted for 49.09% of ownership, reflecting a balanced distribution of shares among the public and promoters. The number of shareholders has gradually increased to 366 by September 2025, indicating a growing interest in the company despite its operational challenges. This interest may stem from the low P/BV ratio, which could attract value investors looking for potential upside. However, the declining promoter stake could also signal potential instability, leading to questions about long-term strategic direction and management commitment.
Outlook, Risks, and Final Insight
Ganga Pharmaceuticals faces several risks that could impact its future performance, including persistent profitability challenges and operational inefficiencies as reflected in its negative OPM and prolonged cash conversion cycle. Despite these headwinds, the relatively low P/BV ratio suggests potential for value appreciation if the company can improve its operational efficiency. The firm must address its high CCC and enhance its revenue consistency to regain investor confidence and improve profitability. A focus on cost control and enhancing product offerings could provide a path forward. In a scenario where Ganga Pharmaceuticals successfully implements strategic initiatives to streamline operations and boost sales, it could potentially enhance profitability and shareholder value. Conversely, failure to address these operational challenges may result in continued investor skepticism and a further decline in market confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 207/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,056.75 Cr | 1,120.77 | 52.60 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.38 | 1.70 | 1.14 | 1.23 | 1.25 | 1.24 | 1.35 | 1.23 | 1.32 | 1.42 | 1.31 | 1.33 | 1.37 |
| Expenses | 1.10 | 1.60 | 1.07 | 1.28 | 1.23 | 1.23 | 1.28 | 1.30 | 1.27 | 1.41 | 1.42 | 1.33 | 1.39 |
| Operating Profit | 0.28 | 0.10 | 0.07 | -0.05 | 0.02 | 0.01 | 0.07 | -0.07 | 0.05 | 0.01 | -0.11 | 0.00 | -0.02 |
| OPM % | 20.29% | 5.88% | 6.14% | -4.07% | 1.60% | 0.81% | 5.19% | -5.69% | 3.79% | 0.70% | -8.40% | 0.00% | -1.46% |
| Other Income | 0.08 | 0.09 | 0.07 | 0.19 | 0.11 | 0.15 | 0.12 | 0.18 | 0.09 | 0.15 | 0.29 | 0.14 | 0.15 |
| Interest | 0.12 | 0.12 | 0.09 | 0.10 | 0.10 | 0.09 | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 |
| Profit before tax | 0.21 | 0.04 | 0.02 | 0.01 | 0.00 | 0.04 | 0.04 | 0.01 | 0.02 | 0.05 | 0.07 | 0.03 | 0.03 |
| Tax % | 23.81% | 25.00% | 50.00% | 100.00% | 25.00% | 25.00% | 0.00% | 50.00% | 20.00% | 57.14% | -66.67% | 33.33% | |
| Net Profit | 0.16 | 0.03 | 0.02 | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 | 0.02 |
| EPS in Rs | 0.39 | 0.07 | 0.05 | 0.00 | 0.00 | 0.07 | 0.07 | 0.02 | 0.05 | 0.06 | 0.04 | 0.12 | 0.03 |
Last Updated: December 26, 2025, 9:06 pm
Below is a detailed analysis of the quarterly data for Ganga Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from 1.33 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Sep 2025, the value is 1.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.33 Cr. (Mar 2025) to 1.39 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -0.02 Cr., marking a decrease of 0.02 Cr..
- For OPM %, as of Sep 2025, the value is -1.46%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -1.46%, marking a decrease of 1.46%.
- For Other Income, as of Sep 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.09 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 33.33%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Mar 2025) to 33.33%, marking an increase of 100.00%.
- For Net Profit, as of Sep 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.04 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.03. The value appears to be declining and may need further review. It has decreased from 0.12 (Mar 2025) to 0.03, marking a decrease of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.66 | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.58 | 2.48 | 2.70 |
| Expenses | 2.43 | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.53 | 2.60 | 2.72 |
| Operating Profit | 0.23 | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0.00 | 0.05 | -0.12 | -0.02 |
| OPM % | 8.65% | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0.00% | 1.94% | -4.84% | -0.74% |
| Other Income | 0.15 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 | 0.29 |
| Interest | 0.30 | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 | 0.16 |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 |
| Profit before tax | 0.05 | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 | 0.06 |
| Tax % | 40.00% | 40.00% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50.00% | 16.67% | 40.00% | 33.33% | 11.11% | |
| Net Profit | 0.03 | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | 0.08 |
| EPS in Rs | 0.13 | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 | 0.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 66.67% | 40.00% | 28.57% | 111.11% | 0.00% | -89.47% | 100.00% | 0.00% | 25.00% | 60.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -26.67% | -11.43% | 82.54% | -111.11% | -89.47% | 189.47% | -100.00% | 25.00% | 35.00% |
Ganga Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -4% |
| 3 Years: | 2% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -16% |
| 3 Years: | 26% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 13% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.33 | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.28 | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.37 |
| Borrowings | 2.07 | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | 1.56 |
| Other Liabilities | 0.46 | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | 0.32 |
| Total Liabilities | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
| Fixed Assets | 0.65 | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.66 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.50 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Other Assets | 4.44 | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9.50 |
| Total Assets | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
Below is a detailed analysis of the balance sheet data for Ganga Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.91 Cr.. The value appears strong and on an upward trend. It has increased from 4.84 Cr. (Mar 2025) to 5.91 Cr., marking an increase of 1.07 Cr..
- For Reserves, as of Sep 2025, the value is 2.37 Cr.. The value appears strong and on an upward trend. It has increased from 2.29 Cr. (Mar 2025) to 2.37 Cr., marking an increase of 0.08 Cr..
- For Borrowings, as of Sep 2025, the value is 1.56 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.42 Cr. (Mar 2025) to 1.56 Cr., marking an increase of 0.14 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.32 Cr.. The value appears to be improving (decreasing). It has decreased from 0.42 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.10 Cr..
- For Total Liabilities, as of Sep 2025, the value is 10.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.66 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.66 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 9.50 Cr.. The value appears strong and on an upward trend. It has increased from 8.31 Cr. (Mar 2025) to 9.50 Cr., marking an increase of 1.19 Cr..
- For Total Assets, as of Sep 2025, the value is 10.16 Cr.. The value appears strong and on an upward trend. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
Notably, the Reserves (2.37 Cr.) exceed the Borrowings (1.56 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.84 | -1.89 | -1.89 | -1.83 | -1.73 | -1.45 | -1.09 | -1.70 | -1.89 | -1.83 | -1.31 | -1.54 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94.68 | 109.20 | 140.04 | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 130.16 | 133.93 |
| Inventory Days | 312.46 | 288.16 | 374.86 | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 |
| Days Payable | 105.08 | 118.01 | 98.65 | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 |
| Cash Conversion Cycle | 302.07 | 279.35 | 416.26 | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 463.04 | 403.19 |
| Working Capital Days | 222.29 | 142.11 | 467.80 | 428.84 | 417.14 | 387.96 | 449.23 | 477.56 | 503.45 | 477.31 | 639.46 | 731.47 |
| ROCE % | 7.87% | 8.03% | 6.80% | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 |
| Diluted EPS (Rs.) | 0.12 | 0.07 | 0.10 | 0.09 | 0.05 |
| Cash EPS (Rs.) | 0.25 | 0.19 | 0.23 | 0.22 | 0.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Revenue From Operations / Share (Rs.) | 5.45 | 5.66 | 6.37 | 6.13 | 5.85 |
| PBDIT / Share (Rs.) | 0.66 | 0.61 | 0.74 | 0.74 | 0.70 |
| PBIT / Share (Rs.) | 0.56 | 0.51 | 0.60 | 0.60 | 0.57 |
| PBT / Share (Rs.) | 0.19 | 0.13 | 0.13 | 0.12 | 0.09 |
| Net Profit / Share (Rs.) | 0.16 | 0.09 | 0.09 | 0.09 | 0.05 |
| PBDIT Margin (%) | 12.12 | 10.86 | 11.71 | 12.08 | 12.01 |
| PBIT Margin (%) | 10.35 | 9.06 | 9.53 | 9.88 | 9.75 |
| PBT Margin (%) | 3.59 | 2.31 | 2.05 | 2.05 | 1.57 |
| Net Profit Margin (%) | 2.99 | 1.70 | 1.51 | 1.52 | 0.85 |
| Return on Networth / Equity (%) | 1.10 | 0.66 | 0.72 | 0.70 | 0.37 |
| Return on Capital Employeed (%) | 3.70 | 3.32 | 4.05 | 3.89 | 3.82 |
| Return On Assets (%) | 0.88 | 0.53 | 0.49 | 0.47 | 0.26 |
| Long Term Debt / Equity (X) | 0.03 | 0.05 | 0.11 | 0.16 | 0.12 |
| Total Debt / Equity (X) | 0.19 | 0.19 | 0.33 | 0.33 | 0.29 |
| Asset Turnover Ratio (%) | 0.29 | 0.32 | 0.32 | 0.31 | 0.31 |
| Current Ratio (X) | 4.28 | 4.81 | 2.72 | 2.91 | 2.86 |
| Quick Ratio (X) | 3.55 | 3.77 | 2.09 | 2.23 | 2.15 |
| Inventory Turnover Ratio (X) | 2.18 | 1.09 | 1.15 | 1.13 | 1.31 |
| Interest Coverage Ratio (X) | 1.79 | 1.61 | 1.56 | 1.54 | 1.47 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 1.25 | 1.20 | 1.19 | 1.10 |
| Enterprise Value (Cr.) | 6.04 | 13.13 | 7.46 | 5.95 | 4.59 |
| EV / Net Operating Revenue (X) | 2.29 | 4.80 | 2.88 | 2.39 | 1.93 |
| EV / EBITDA (X) | 18.89 | 44.20 | 24.61 | 19.80 | 16.09 |
| MarketCap / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| Price / BV (X) | 0.68 | 1.67 | 1.04 | 0.76 | 0.56 |
| Price / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| EarningsYield | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ganga Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.12, marking an increase of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has increased from 0.19 (Mar 24) to 0.25, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.45. It has decreased from 5.66 (Mar 24) to 5.45, marking a decrease of 0.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 2. It has increased from 0.61 (Mar 24) to 0.66, marking an increase of 0.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.56. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.56, marking an increase of 0.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.16, marking an increase of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.86 (Mar 24) to 12.12, marking an increase of 1.26.
- For PBIT Margin (%), as of Mar 25, the value is 10.35. This value is within the healthy range. It has increased from 9.06 (Mar 24) to 10.35, marking an increase of 1.29.
- For PBT Margin (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 10. It has increased from 2.31 (Mar 24) to 3.59, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.99, marking an increase of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 15. It has increased from 0.66 (Mar 24) to 1.10, marking an increase of 0.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.70. This value is below the healthy minimum of 10. It has increased from 3.32 (Mar 24) to 3.70, marking an increase of 0.38.
- For Return On Assets (%), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 5. It has increased from 0.53 (Mar 24) to 0.88, marking an increase of 0.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 24) to 0.03, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.19.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.29. It has decreased from 0.32 (Mar 24) to 0.29, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 4.28. This value exceeds the healthy maximum of 3. It has decreased from 4.81 (Mar 24) to 4.28, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 2. It has decreased from 3.77 (Mar 24) to 3.55, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 4. It has increased from 1.09 (Mar 24) to 2.18, marking an increase of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 1.61 (Mar 24) to 1.79, marking an increase of 0.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has increased from 1.25 (Mar 24) to 1.44, marking an increase of 0.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.04. It has decreased from 13.13 (Mar 24) to 6.04, marking a decrease of 7.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.80 (Mar 24) to 2.29, marking a decrease of 2.51.
- For EV / EBITDA (X), as of Mar 25, the value is 18.89. This value exceeds the healthy maximum of 15. It has decreased from 44.20 (Mar 24) to 18.89, marking a decrease of 25.31.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.67 (Mar 24) to 0.68, marking a decrease of 0.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ganga Pharmaceuticals Ltd:
- Net Profit Margin: 2.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 86.2 (Industry average Stock P/E: 52.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Gangatat, Dhanvantary Marg, Palghar Maharashtra 401305 | ayurvedganga@gmail.com www.ayurvedganga.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay Vyankatesh Kulkarni | Chairman & Non-Exe.Director |
| Mr. Bharat Brijmohan Sharma | Managing Director & CEO |
| Mrs. Srijna Bharat Sharma | Whole Time Director |
| Mr. Munna Baijnath Chaurasia | Independent Director |
| Mr. Aman Mukesh Chaudhari | Independent Director |
FAQ
What is the intrinsic value of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd's intrinsic value (as of 17 January 2026) is ₹11.13 which is 4.87% lower the current market price of ₹11.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6.90 Cr. market cap, FY2025-2026 high/low of ₹17.0/9.25, reserves of ₹2.37 Cr, and liabilities of ₹10.16 Cr.
What is the Market Cap of Ganga Pharmaceuticals Ltd?
The Market Cap of Ganga Pharmaceuticals Ltd is 6.90 Cr..
What is the current Stock Price of Ganga Pharmaceuticals Ltd as on 17 January 2026?
The current stock price of Ganga Pharmaceuticals Ltd as on 17 January 2026 is ₹11.7.
What is the High / Low of Ganga Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ganga Pharmaceuticals Ltd stocks is ₹17.0/9.25.
What is the Stock P/E of Ganga Pharmaceuticals Ltd?
The Stock P/E of Ganga Pharmaceuticals Ltd is 86.2.
What is the Book Value of Ganga Pharmaceuticals Ltd?
The Book Value of Ganga Pharmaceuticals Ltd is 14.0.
What is the Dividend Yield of Ganga Pharmaceuticals Ltd?
The Dividend Yield of Ganga Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Ganga Pharmaceuticals Ltd?
The ROCE of Ganga Pharmaceuticals Ltd is 3.18 %.
What is the ROE of Ganga Pharmaceuticals Ltd?
The ROE of Ganga Pharmaceuticals Ltd is 1.13 %.
What is the Face Value of Ganga Pharmaceuticals Ltd?
The Face Value of Ganga Pharmaceuticals Ltd is 10.0.